← brief for 2026-09-05 · Slowing decline

LP533401 treatment alters vitamin K metabolism, bone Gla-OC/Glu-OC ratios, and improves mineral status of the skeleton in rats with chronic kidney disease

Key takeaways

A drug called LP533401 changed how rats with chronic kidney disease handled vitamin K and improved the mineral content of their bones. Kidney disease weakens bones and throws off the body's calcium and phosphate balance, so this points at one possible way to protect the skeleton. The work was done in rats, not people, so it is early.

Who did this work

Magdalena Kopańko (Medical University of Białystok) · Beata Sieklucka (Medical University of Białystok) · Dariusz Pawlak (Medical University of Białystok) · Magdalena Zabłudowska (Medical University of Białystok) · Katarzyna Sokołowska (Medical University of Białystok) · Urszula Łebkowska (Medical University of Białystok) · Krystyna Pawlak (Medical University of Białystok)

Source

Paper · OpenAlex, CKD works · 2026-09-04
https://doi.org/10.3389/fphar.2026.1793663